GeoVax Advances GEO-MVA Vaccine Development Amid Rising Mpox Threat

GeoVax Labs, Inc., a clinical-stage biotechnology company, is making significant strides in the development of its GEO-MVA vaccine, targeting the growing public health threat posed by Mpox and smallpox. With global cases on the rise and a bipartisan push for pandemic preparedness, the company's efforts are gaining momentum. The European Medicines Agency (EMA) has provided favorable regulatory input, placing GEO-MVA on an expedited path toward market access. This development not only accelerates GeoVax's regulatory approval and commercialization timeline but also highlights the vaccine's potential to meet urgent public health needs.

The GEO-MVA vaccine is part of GeoVax's modern platform, which includes a development-stage continuous avian cell line process. This innovative approach is expected to enhance the production of MVA-based vaccines, enabling quicker responses to epidemics and pandemics, reducing production costs, and facilitating local manufacturing. The urgency for additional MVA-vaccine supply options has been underscored by confirmed Mpox cases across the U.S., Europe, and new outbreaks in West and Central Africa.

David Dodd, Chairman and CEO of GeoVax, emphasized the importance of diversifying stockpile planning. The GEO-MVA vaccine is poised to serve as a complementary or alternative solution, addressing the limitations of current, single-source options. This expansion in vaccine supply options is critical for public health worldwide, offering a much-needed alternative in the face of high-consequence threats like smallpox.

GeoVax's recent receipt of favorable Scientific Advice from the EMA marks a significant milestone, enhancing the vaccine's standing with international regulatory bodies and opening up revenue-generating opportunities across Europe and beyond. Additionally, the company's proposal under the Biomedical Advanced Research and Development Authority's (BARDA) Rapid Response Partnership Vehicle (RRPV) is under review, aiming to fund scalable vaccine platforms and reduce dependency on stockpiling for high-consequence threats.

The advancement of the GEO-MVA vaccine represents a critical step forward in addressing the global Mpox threat, showcasing GeoVax's commitment to developing innovative solutions for infectious diseases. With regulatory pathways clearing and the potential for expanded vaccine supply, the company is at the forefront of pandemic preparedness and response.